Oxford Immunotec (OXFD) Tops Q3 EPS by 15c, Raises Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Oxford Immunotec Reports Third Quarter 2016 Financial Results
November 1, 2016 7:00 AM EDTThird quarter revenue of $26.1 million, an increase of 46% compared to prior year periodTuberculosis revenue of $22.0 million, an increase of 23% compared to prior year periodTick-borne disease and other revenue of $4.1 millionCompleted acquisitions of Imugen and Immunetics expanding offerings in the tick-borne disease testing marketRaising revenue guidance for the full year from $82.5-$84.5 million to $85.0-$85.8 million
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company focused on developing and... More
